Company intelligence / Profile preview

ProDigest

Gent, East Flanders, Belgiumprodigest.eu ↗

Ownership: Private
Development stage: Other

Overview

ProDigest provides advanced in vitro/ex vivo gastrointestinal tract simulation platforms to model human and animal gut physiology and microbiology. Their flagship SHIME® technology enables detailed study of the fate, metabolism, efficacy, and safety of food ingredients or pharmaceuticals before clinical trials. The company has been recognized by the FDA for its validated preclinical GI models.

Therapeutic areas: GastroenterologyMetabolic Disorders
Modalities: In vitro simulation models (e.g., SHIME®)Ex vivo simulation modelsMetabolomics platform (MetaKey®)Microbial therapy (for live biotherapeutic products and probiotics research)
Industry: Drug Discovery Services

Partnerships

US Food & Drug Administration National Center for Toxicological Research

Beyond the preview

Go deeper on ProDigest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProDigest.

Explore the full profile